121 related articles for article (PubMed ID: 26187009)
1. Stopping MYC in its tracks.
Stefan E; Hart JR; Bister K
Aging (Albany NY); 2015 Jul; 7(7):463-4. PubMed ID: 26187009
[No Abstract] [Full Text] [Related]
2. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.
Shi J; Stover JS; Whitby LR; Vogt PK; Boger DL
Bioorg Med Chem Lett; 2009 Nov; 19(21):6038-41. PubMed ID: 19800226
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization.
Lu X; Vogt PK; Boger DL; Lunec J
Oncol Rep; 2008 Mar; 19(3):825-30. PubMed ID: 18288422
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
Berg T
Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.
Guo J; Parise RA; Joseph E; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
Cancer Chemother Pharmacol; 2009 Mar; 63(4):615-25. PubMed ID: 18509642
[TBL] [Abstract][Full Text] [Related]
7. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
[TBL] [Abstract][Full Text] [Related]
8. Novel molecule hits key cancer target.
Cancer Discov; 2014 Nov; 4(11):OF8. PubMed ID: 25367970
[No Abstract] [Full Text] [Related]
9. Zinc modulates c-Myc/Mad1 balance in human leukemia cells.
Sirinian MI; Pisegna S; Paroli M; Militi S; Testa U; Peschle C
Leukemia; 2003 Jan; 17(1):272-4. PubMed ID: 12529695
[No Abstract] [Full Text] [Related]
10. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
13. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
Link JM; Hurlin PJ
Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
[TBL] [Abstract][Full Text] [Related]
14. MYC needs MNT.
Link JM; Hurlin PJ
Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
[No Abstract] [Full Text] [Related]
15. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J; DiFeo A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
[No Abstract] [Full Text] [Related]
16. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
17. Taking myc to the max.
Turner R
Nat Struct Biol; 2003 Mar; 10(3):157. PubMed ID: 12605219
[No Abstract] [Full Text] [Related]
18. CDC6 interacts with c-Myc to inhibit E-box-dependent transcription by abrogating c-Myc/Max complex.
Takayama M; Taira T; Iguchi-Ariga SM; Ariga H
FEBS Lett; 2000 Jul; 477(1-2):43-8. PubMed ID: 10899308
[TBL] [Abstract][Full Text] [Related]
19. More than MAX: Discovering the Myc interactome.
Kalkat M; Wasylishen AR; Kim SS; Penn L
Cell Cycle; 2011 Feb; 10(3):374-5. PubMed ID: 21270515
[No Abstract] [Full Text] [Related]
20. Cytokine-induced inhibition of Myc activity in monocytic cells.
Larsson LG; Bahram F; Wu S; Oberg F; Nilsson K; Lüscher B
Curr Top Microbiol Immunol; 1997; 224():191-200. PubMed ID: 9308242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
